Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 17,766 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, Placebo, Sitagliptin 100mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more

Conditions: Breastfeeding
Interventions: Telelactation services; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Aging
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 70 Years to 95 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Premature; Infant, Light-for-dates
Interventions: Cue directed tactile stimulation; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 7 Days to 4 Months
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Death; Neonatal, Morbidity;Newborn
Interventions: Teleneonatology; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 0 Days and older
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Anchorage, Alaska • Juneau, Alaska • Ketchikan, Alaska + 17 more

Conditions: Control Condition, How Incentive Receive, How Incentive Holdout, How Incentive Ineligible, How and Why Incentive Receive, How and Why Incentive Holdout, How and Why Incentive Ineligible
Interventions: How Nudge, How and Why Nudge, Incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 60,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: eteplirsen; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 6 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 9 more

Conditions: Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
Interventions: Group 1: Placebo, Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 84
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 81 more

Conditions: Student Behavior
Interventions: In the Drivers Seat, School bus driver training videos; Behavioral
Lead sponsor: Oregon Center for Applied Science, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 710 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Pain
Interventions: Patient-controlled analgesia, morphine; Device · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Prevention
Interventions: WePrEP: A shared decision-making tool, Active comparator: CDC recommendations for discussing PrEP; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sheridan, Colorado

Conditions: Pre-diabetes
Interventions: BREAK, ONE; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Substance Use Disorders, Mental Illness
Interventions: SBIRT, Health Education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 1,080 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • Oxnard, California

Conditions: Alzheimer's Disease
Interventions: Placebo, CAD106; Biological
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more

Conditions: Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions: Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo; Combination Product · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 65 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Post-Traumatic Stress Disorder
Interventions: Healing Touch & Guided Imagery; Other
Lead sponsor: Scripps Center for Integrative Medicine; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions: Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium; Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Stenosis, Coronary Occlusion
Interventions: Percutaneous Coronary Intervention; Other
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Urologic Surgical Procedure
Interventions: Ice pack; Other
Lead sponsor: Viraj Master; Other
Eligibility: 18 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Chronic Idiopathic Constipation
Interventions: Plecanatide, Matching placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 36
States / cities: Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more

Conditions: Cardiovascular Disease
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 936 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 41
States / cities: Los Angeles, California • Torrance, California • Boulder, Colorado + 36 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Aim 2 Exercise group, Aim 1 Exercise Dosing, Aim 2 Control group; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 10 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Expanding Rural Access to Breastfeeding Support Via Telehealth: The Tele-MILC Trial

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

Cue-based Tactile Stimulation and Infant Stress Reactivity

The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals

How v. How and Why Nudges and Rewards

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Multimedia Program to Promote Positive Bus Behavior

Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department

WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

Healing Touch & Guided Imagery for Posttraumatic Stress Disorder Symptoms

Severe Sepsis in Children - IMPRESS-C

Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package

Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Strength Training in Duchenne Muscular Dystrophy